Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

/a>

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL, that the substitution of pixantrone for doxorubicin in the CHOP regimen may not produces complete remissions and long-term disease free survival in patients with relapsed or refractory, aggressive NHL who previously failed frontline CHOP therapy, that there may not be a correlation between CR/CRu's and progression free survival, that pixantrone may not show an overall improvement rate in survival for patients independent of factors known to influence survival, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials or the total number of patients enrolled, that CTI cannot predict whether PIX-R will serve as either a post-marketing commitment trial or as a pivotal trial, that CTI cannot predict the outcome of the formal dispute resolution process with the FDA, that the FDA may not make its decision on the appeal in the second quarter of 2011, that the FDA may request additional clinical trials, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/w3n5p6/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. The delivery of drugs ... in the treatment of neurological disorders. Drugs may ... systematically (e.g., by intravenous injection) for targeted action ...
(Date:6/2/2015)... June 2, 2015 The Canadian Society for Vascular ... tests, treatments or procedures that are commonly ordered ... part of Choosing Wisely Canada.  The list identifies ... conversations between patients and physicians about what care ... for Vascular Surgery,s list identified the following five ...
(Date:6/2/2015)... , June 02, 2015 Research and Markets ( ... Archiving and Communication Systems (PACS) - Global Strategic Business Report" ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... and forecasts are provided for the period 2014 through 2020. ...
Breaking Medicine Technology:Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 2As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 4Picture Archiving and Communication Systems (PACS) - Global Strategic Business Report 2015: User Demand Favors Integrated RIS/PACS Solutions 2
... Bend Research Inc. ( www.bendresearch.com ), a leading independent ... McLeod has joined the company as Chief Financial Officer. ... McLeod was formerly Director of Business Development with ... strategic vision is credited with improving many different parts ...
... 2011 Comprehensive Care Corporation (OTC BB: CHCR), which ... services for managed care companies throughout the U.S., today ... been praised by the Chamber of Commerce of the ... Advisory Council in "helping to shape and drive the ...
Cached Medicine Technology:Bend Research Announces New Chief Financial Officer 2Comprehensive Care Corporation CEO Clark A. Marcus Praised for U.S. Chamber of Commerce Service 2
(Date:6/2/2015)... The Down Syndrome Association of Wisconsin (DSAW) is ... Glee as the keynote speaker for its June 6, ... The event aims to raise funds to support programs ... counties. , "We couldn't be more ... event," says Dawn Nuoffer, DSAW Executive Director. "She's a ...
(Date:6/2/2015)... New Jersey (PRWEB) June 02, 2015 ... (Horizon BCBSNJ) announced today that its Walking and Wellness ... Classic Presented by Acer, has raised another $3,000 for ... Natalie Gulbis undertook the challenge, recording 32,000 steps on ... at Stockton Seaview Hotel & Golf Club in Galloway ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 “ Radaris ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... the data they need on a person. , According to ... publication even goes on to explain that curiosity is a ...
(Date:6/2/2015)... October 1, 2015 the transition to ICD-10 will happen ... Monday, June 1st Congressman Kevin Brady, chairman of ... Committee, and 12 members of the Committee sent a ... the administration to provide a smooth transition for local ... newest coding system for healthcare professionals to code diseases, ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Claflin ... distributor, has announced the acquisition of RSI ... distributor, effective May 29th, 2015. , With CME’s recent ... this latest acquisition joins three premier organizations which specialize ... hospitals and healthcare facilities. By combining forces, they now ...
Breaking Medicine News(10 mins):Health News:Glee star Lauren Potter helps Down Syndrome Association of WI raise awareness, support 2Health News:LPGA’s Natalie Gulbis Raises an Additional $3,000 for the Boys & Girls Club of Atlantic City Through Horizon BCBSNJ’s Walking and Wellness Challenge 2Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4Health News:Claflin Medical Equipment (CME) Announces Acquisition of RSI Equipment, Inc. 2
... , AUGUSTA, Ga. Scientists want to protect the optic nerve ... a car wreck. It,s called traumatic optic nerve damage when ... gets rattled, resulting in swelling and inflammation that can destroy its ... loss and blindness. "The optic nerve is not completely straight ...
... has named Takeo Kanade, the U.A. and Helen Whitaker ... Mellon University, the 2010 winner of the ACM/AAAI Allen ... and robotics. , The Newell Award, named for one ... Computer Science, recognizes career contributions that have breadth within ...
... lead-based ammunition as a potential health and environmental hazard, ... material for bullets tungsten may not be ... accumulates in major structures of the immune system in ... Toxicology . Jose Centeno and colleagues explain that ...
... 2011) Breast cancer is the second most common cancer ... Being exposed to estrogen over a long period of time ... developing the disease. One way a woman can combat ... tamoxifen, which interferes with the activity of estrogen. Now, ...
... not really be compatible with current beauty ideals, but, to a ... our body. However, it is a different matter if the organism ... This is a clear sign of a metabolic disorder. ... which is regarded a typical characteristic of the dangerous metabolic syndrome. ...
... , TUESDAY, April 5 (HealthDay News) -- In the ... researchers report that risks to postmenopausal women who were ... the treatment. The study found that when ... blood clots, which were elevated while they were on ...
Cached Medicine News:Health News:Better treatment sought for blinding traumatic optic nerve damage 2Health News:CMU's Takeo Kanade wins ACM/AAAI Award for career contributions to computer vision, robotics 2Health News:Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen 2Health News:Fatty liver -- how a serious problem arises 2Health News:Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends 2Health News:Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends 3
... The Stryker Threaded Dilator ... yet another choice for ... Dilators provide compaction reaming ... compaction of bone within ...
... The Arthroscopy Scissor is ideal for excising ... tissue debris in the joint. The serrated edge ... as well as hold tissue within the jaws ... left and right jaw curvatures, are the perfect ...
... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ... size and angle required for large and ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
Medicine Products: